Decoded

What does it take for a 130-year-old company to remain at the forefront of pharmaceutical innovation?

In this episode of Decoded, Dr. Jurgi Camblong sits down with André Hoffmann, Vice-Chair of Roche and the fourth generation of the Hoffmann family to lead the company since 1896, to discuss how genomics and AI are transforming pharmaceutical innovation and what organizational structures enable long-term thinking in business.

André has spent his career at one of the world's largest pharmaceutical companies, observing how the industry is adapting to new technologies and changing approaches to drug discovery. He brings perspective on how companies can invest in long-term innovation cycles, the strategic considerations of different ownership models, and how businesses measure value and impact.

You'll hear:

* How genomics is dismantling the blockbuster playbook
* Where AI fits into modern drug discovery and development
* The talent, infrastructure, and mindset shifts this requires
* Why 130 years of family ownership is a business superpower
* How new accounting systems can measure what we actually take from nature
* What real success looks like (hint: it's not in your bank account) 

This is a conversation about the intersection of technology, business structure, and purpose in modern pharma. André shares insights on ownership models, innovation timelines, how organizations adapt to precision medicine, and why the way we measure success in business needs to evolve. 

What if AI's biggest threat is not a smarter machine, but a less curious human?

In this episode of Decoded, Dr. Jurgi Camblong sits down with Pr. Joseph Sifakis, Turing Award laureate and inventor of model checking, the mathematical method that taught machines to prove their own correctness. Joseph has spent fifty years building the foundations of systems we can trust.

Now he is asking whether we are ready to trust them with our minds.

You'll hear:
•Why current AI cannot reason and what real autonomy would actually require
•Does the difference between symbolic and connectionist AI actually matter?
•Why being correct is not enough: systems also need values and accountability
•Why human cognitive dependence, not superintelligence, is the risk that worries him most
•What he tells young people about living a life worth living
A rigorous, clear-eyed, and unexpectedly hopeful conversation about intelligence; human and artificial.

For more information on this episode follow the link below:
https://www.linkedin.com/in/jurgicamblong/ 
https://www.sophiagenetics.com/podcasts/

What if healthcare systems aren't broken — they're just built for the wrong job?

In this episode of Decoded, Dr. Jurgi Camblong sits down with Lord David Prior, who spent years running the NHS from the inside, to explore why shifting from sick care to health care — powered by AI and data-driven medicine — may be healthcare's next real leap forward.

From investment banking to restructuring British Steel to leading the NHS, David has spent his career inside institutions at moments of change. Few people remain this optimistic about what comes next.

You'll hear:

• Why treating illness late is the wrong model
• How data-driven medicine could widen access to good care
• What's really standing between genomics and everyday care
• Why David compares healthcare today to Henry Ford's Model T

A candid, optimistic conversation about building healthcare for the world we actually live in.

For more information on this episode follow the link below:
https://www.linkedin.com/in/jurgicamblong/ 
https://www.sophiagenetics.com/podcasts/

What does it take to ask one question — *how do you free software from hardware?* — and end up reshaping the entire computing industry? In this episode of Decoded, Dr. Jurgi Camblong speaks with Edouard Bugnion, co-founder of VMware and Vice President for Innovation and Impact at EPFL, the Swiss Federal Institute of Technology in Lausanne. VMware didn't just build a product. It built the foundation on which the modern cloud was built — and was acquired by Broadcom in 2023 for $69 billion. From a childhood in Neuchâtel to a PhD at Stanford, from research lab to billion-dollar company, and back to Switzerland as a professor and public advisor, Edouard has spent his career at the precise intersection of deep science and real-world impact. You'll hear how a single idea about separating software from hardware gave birth to an industry, what the dot-com crash taught him about building through uncertainty, the three factors he believes determine whether a company succeeds or fails, why the energy cost of AI is a problem that can't be wished away, and what it actually means to be responsible when innovation moves faster than society can keep up. This episode is about what happens when a scientist becomes a builder, and why the most important question in technology right now may not be *what can AI do* — but *what should it do.*

What does it take to turn a two-person startup in Paris into a $6.8 billion exit, and then do it all over again for 200 other founders?

In this episode of Decoded, Dr. Jurgi Camblong speaks with Bernard Liautaud, co-founder of BusinessObjects and Managing Partner at Balderton Capital, one of Europe's leading venture capital firms backing category-defining companies like Revolut, Wayve, and Quantum Systems.

Bernard didn't just build a company. He built a category. Starting with two people in Paris in 1990, he helped define what business intelligence could be, took the company to NASDAQ, and sold it to SAP for $6.8 billion. Then he turned that experience into fuel for the next generation of European founders.

You'll hear why Europe's VC returns have quietly outperformed the US, how Balderton evaluates founders and the one trait they call "insurgency," what the story of Revolut reveals about the power of execution, why Bernard believes Europe has not just the talent but the values to build AI responsibly, and the philosophy behind his most personal insight: as a VC, you have many shots. As a founder, you have one.

This episode is about what happens when ambition meets experience, and why Europe's most exciting chapter may still be ahead of us.

What happens when a world-class biologist decides that academic research isn't moving fast enough for patients? 

Dr. Keith Flaherty is a physician, scientist, and founder who obsesses over the "wiring of cells". As the Director of Clinical Research at the Mass General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School, he has authored over 300 peer-reviewed research publications. But he didn't stop at academia. He went on to co-found Loxo Oncology and Scorpion Therapeutics, driving billions in acquisitions and fundamentally changing precision cancer care. 

In this episode, Keith joins Dr. Jurgi Camblong to discuss his journey from early cell biology to becoming president of the AACR. They explore the evolution of melanoma treatments, the mechanics of targeted inhibitors, and the friction in the system that prevents us from learning from every patient. 

Because better outcomes don’t come from better science alone. They come from making the whole system work. 

#Oncology #PrecisionMedicine #AACR #DrugDevelopment #DecodedPodcast

What happens when the mind behind the Mars Rovers turns its attention to fighting cancer and developing next-generation medicines?
Today, Thomas Fuchs is the Chief AI Officer at Eli Lilly & Company, but he started his career at NASA, building the AI that helped rovers navigate the surface of Mars. He soon realized that the same math used to distinguish sand from rocks could be used to identify cancer cells on a pathology slide. He transitioned to healthcare, coined the term "computational pathology", and secured the first-ever FDA approval for an AI solution in cancer pathology after founding Paige.ai.
In this episode, Thomas joins Dr. Jurgi Camblong to discuss his journey, including how to build trust around AI, the massive potential of the technology for medicine discovery, and what the future holds for medicine.

Because better outcomes don’t come from better algorithms alone—they come from pioneers brave enough to trust them.

For more information on this episode follow the link below:
https://www.linkedin.com/in/jurgicamblong/
https://www.sophiagenetics.com/podcasts/

#AIinHealthcare #DrugDiscovery #GenerativeAI #EliLilly #DecodedPodcast

Most doctors look at a tumor and see a disease. Professor Olivier Michielin sees a code waiting to be cracked. 

Starting his career in physics and training under Nobel Prize winner Martin Karplus, Olivier realized early on that he "would not be happy just talking to electrons". He pivoted to medicine to bring a data-driven, engineering mindset to oncology. Today, he is rewriting the rules of how we treat melanoma and other complex cancers by combining immunotherapy with advanced algorithms. 

In this episode, the "Tumor Hacker" joins Dr. Jurgi Camblong to discuss how he is using physics, AI, and immunotherapy to rewrite the future of oncology. From training with Nobel laureates to leading oncology at HUG, Olivier explains why the future of medicine isn’t about discovering cures by accident - it’s about engineering them by design. 

A conversation about the convergence of data, biology, and the human immune system. 

For more information on this episode follow the link below:

https://www.linkedin.com/in/jurgicamblong/
https://www.sophiagenetics.com/podcasts/

#Oncology #Immunotherapy #AIinHealthcare #PrecisionMedicine #DecodedPodcast

Are we practicing healthcare, or just "sick care"?

In this episode of Decoded, Jurgi Camblong sits down with Dr. Michael Snyder, Chair of Genetics at Stanford Medicine and one of the most cited scientists in the world, to challenge the status quo of modern medicine.

We monitor our cars with dashboards to prevent breakdowns, yet we wait until our bodies fail before seeking help. Dr. Snyder explains why the future of medicine isn't about treating illness—it's about predicting it.

In this episode, we cover:

The "Sick Care" Crisis: Why our current system is designed to fail and how to fix it.

The Body Dashboard: Using big data, AI, and wearables to monitor health in real-time.

Redefining Aging: How deep metabolic profiling can help us live longer, healthier lives.

The Future of Diagnostics: Moving from reactive treatments to proactive precision care.

Tune in to hear how data is rewriting the rules of human longevity.

Longevity is not luck. It is biology, variation, and human resilience expressed across generations - and we are only beginning to understand it. And few people have studied longevity more deeply than Professor Mayana Zatz, whose work with centenarians and supercentenarians is reshaping what we know about aging.

In this episode of Decoded, Dr. Jurgi Camblong speaks with one of the world’s leading geneticists and a pioneer in rare diseases, aging, and human longevity.

Based at the University of São Paulo, Mayana has followed more than 100,000 families to understand why some people develop severe genetic conditions while others remain healthy into their 90s, 100s, and beyond.

Together, they explore:

• What centenarians and supercentenarians reveal about healthy aging 
• Why some individuals stay healthy despite carrying high-risk mutations
• How genetic resilience may inspire future gene therapies
• What large family cohorts teach us about rare diseases and long-term health
• The role of prevention in the next era of medicine
• Why affordability must be part of the future of genetic treatments

A conversation that brings together genetics, aging research, and the real human stories behind long life. A deeper look at what it means to live longer, and live well.

#Longevity #Genetics #Aging #Centenarians #Supercentenarians #RareDisease #HumanResilience #GeneTherapy #HealthyAging #GenomicResearch #DecodedPodcast